Auto-discovered from 2 recent studies; not yet curated.
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 100
Journal of gynecologic oncology · Sep 2024 · Phase III randomized controlled trial, randomized 1:1
Bevacizumabepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancer This randomized phase III trial assigned 100 Chinese patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube, or primary peritoneal cancer after surgery to carboplatin/paclitaxel with either bevacizumab or placebo. Median progression-free survival was 22.6 months with bevacizumab plus chemotherapy versus 12.3 months with placebo plus chemotherapy (stratified HR 0.30, 95% CI 0.17–0.53). Treatment-related grade 3/4 adverse events were more frequent in the bevacizumab arm.
Reported effects: median PFS 22.6 mo · stratified hazard ratio for PFS 0.3 [0.17–0.53] · +1 more
Studied with: carboplatin, paclitaxel.
Key findings
- Of randomized patients, 51 received bevacizumab + CP and 49 received placebo + CP.
- Median PFS was 22.6 months with bevacizumab + CP (95% confidence interval [CI]=18.6, not estimable) and 12.3 months (95% CI=9.5, 15.0) with placebo + CP (stratified hazard ratio=0.30; 95% CI=0.17, 0.53).
- Treatment-related grade 3/4 adverse events occurred in 46 of 49 (94%) patients receiving bevacizumab + CP, and 34 of 50 (68%) receiving placebo + CP.
Limitations: Relatively small randomized sample (100 patients).; Primary endpoint was investigator-assessed PFS (no central review stated).; Overall survival and longer-term outcomes not reported in the abstract.; Single-country (China) population may limit generalizability to other populations.; Adverse-event denominators reported in the abstract are inconsistent with the randomized-arm counts, which complicates interpretation of safety rates..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Key findings
- The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
- Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
- Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
- PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
- For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Cancer cell international · May 2023 · review
Bevacizumabneurofibromatosis type 2vestibular schwannomameningiomaependymoma This is a narrative review describing the clinical features, genetic causes, and current management options for neurofibromatosis type 2 (NF2). The authors summarize that NF2 is caused by loss-of-function mutations in the NF2 gene leading to merlin dysfunction, list standard management approaches including surgery, radiosurgery, bevacizumab and observation, and note recent genetic and molecular advances that may enable targeted therapies but also challenges to implementation.
Key findings
- NF2 is characterized by multiple benign nervous-system tumors, most commonly bilateral vestibular schwannoma, meningioma, and ependymoma.
- Clinical manifestations depend on tumor site; vestibular schwannoma causes hearing loss, dizziness, and tinnitus; spinal tumors cause pain, weakness, or paresthesias.
- Clinical diagnosis is based on the Manchester criteria, which have been updated in the last decade.
- NF2 is caused by loss-of-function mutations in the NF2 gene on chromosome 22 resulting in merlin protein malfunction.
- Over half of NF2 patients have de novo mutations, and about half of that group are mosaic.
- Management options include surgery, stereotactic radiosurgery, bevacizumab, and close observation.
- Multiple tumors, inoperable disease, complications of surgery, radiotherapy-induced malignancies, and poor effectiveness of cytotoxic chemotherapy have driven interest in targeted therapies.
- Recent advances in genetics and molecular biology have enabled identification and potential targeting of pathways involved in NF2 pathogenesis, but there are challenges to translating this into effective therapies.
Limitations: Narrative review with no original experimental or clinical data presented.; No systematic review or meta-analytic methods described in the abstract; potential for selection or narrative bias.; The abstract does not provide quantitative efficacy or safety data for therapies mentioned.; Discussion of potential targeted therapies is descriptive and does not present new clinical trial evidence in this article..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewTrialMixed resultsLimited evidenceTier 4 · clinical
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Jan 2023 · narrative review of clinical trials and case reports
Bevacizumabmucinous ovarian carcinomaepithelial ovarian cancer This narrative review searched the literature from January 2009 to June 2021 and identified 21 studies addressing targeted therapy in mucinous ovarian carcinoma. The review found 11 different targeted therapies overall and highlighted several agents (bevacizumab, trastuzumab, nintedanib, AZD1775, sunitinib, cediranib, pazopanib) that warrant further investigation, recommending more clinical trials focussed on this rare tumor type.
Studied with: chemotherapy, other targeted therapies.
Key findings
- From 684 records, 21 studies met the criteria to be included in the review.
- A total of 11 different targeted therapies were identified across the included studies.
- Targeted therapies identified that warrant further investigation include bevacizumab, trastuzumab, nintedanib, AZD1775, sunitinib, cediranib and pazopanib.
- Many therapeutic agents may be investigated further in combination with other targeted therapies or chemotherapy.
- More clinical trials specifically in patients with mucinous ovarian cancer are required; multinational efforts are likely needed for such rare tumours.
Limitations: Narrative review (not a systematic review or meta-analysis) with no quantitative synthesis reported in the abstract.; Rare tumour type with limited and heterogeneous clinical evidence (only 21 studies met inclusion).; The abstract does not report pooled efficacy or safety outcomes, sample sizes, or trial quality.; Recommendations are based on limited available studies and case reports rather than large, definitive trials..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportReported positiveLimited evidenceTier 3 · early humann = 1
Experimental and therapeutic medicine · Jul 2022 · case report
This is a case report of a 61-year-old woman with stage IIIC ovarian carcinosarcoma who underwent extensive cytoreductive surgery followed by six cycles of carboplatin, paclitaxel and bevacizumab. Bevacizumab was not continued after chemotherapy because of severe myelosuppression and cost; the patient then received oral niraparib maintenance. At 6 months after the sixth chemotherapy, CA-125 fell to 4.55 U/ml and imaging plus tumor marker assessment indicated remission at short-term follow-up. The report suggests combined surgery, chemotherapy and targeted maintenance was associated with a favorable short-term outcome in this single patient.
Reported effects: number_of_chemotherapy_cycles 6, n=1 · CA-125 at 6 months 4.55, n=1 · +1 more
Studied with: carboplatin, paclitaxel, bevacizumab.
Key findings
- Extensive cytoreductive surgery performed (sub-extensive hysterectomy, bilateral adnexectomy, sigmoid colon and partial rectal resection, lymph node dissection).
- Postoperative pathology confirmed ovarian carcinosarcoma with serous carcinoma and squamous carcinoma components; sarcomatous elements included fibrosarcoma, chondrosarcoma and rhabdomyosarcoma.
- Patient staged as FIGO IIIC and TNM T3cN1M0.
- The patient received six cycles of carboplatin, paclitaxel plus bevacizumab.
- Severe myelosuppression occurred during and after chemotherapy; bevacizumab was not maintained after chemotherapy (also noted to be expensive).
- Following chemotherapy the patient received oral niraparib maintenance therapy.
- At 6 months after the sixth chemotherapy, cancer antigen 125 levels dropped to 4.55 U/ml (within normal range).
- Short-term 6-month follow-up by ultrasonography, CT, MRI and serum tumor markers indicated a remission prognosis.
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveLimited evidenceTier 4 · clinical
International journal of molecular sciences · Jun 2022 · narrative review
This is a narrative review summarizing current glioblastoma management and future research directions. It states standard care remains maximal safe resection plus radiotherapy and temozolomide, with bevacizumab used in the recurrent setting, and reviews investigational approaches including immunotherapy, new synthetic molecules, natural compounds at preclinical stages, and glioblastoma stem cell inhibition. The authors conclude that prognosis remains poor and that combined strategies and improved delivery methods may enhance standard therapy in the future.
Studied with: maximal safe surgical resection, radiotherapy, temozolomide, bevacizumab, immunotherapy, synthetic molecules, natural compounds, glioblastoma stem cell inhibition.
Key findings
- Current standard management of glioblastoma is maximal safe surgical resection, radiotherapy, and chemotherapy with temozolomide.
- Bevacizumab has been added to the treatment options for recurrent glioblastoma.
- The review summarizes ongoing research and future perspectives on immunotherapy, new synthetic molecules, and natural compounds that are potential future therapies at preclinical stages.
- Despite research advances, glioblastoma management has had minimal changes and prognosis remains poor.
- Combined therapeutic strategies and delivery methods, including immunotherapy, synthetic molecules, natural compounds, and glioblastoma stem cell inhibition, may potentiate standard of care therapy.
Limitations: Narrative review that does not present new primary data.; Many candidate therapies discussed are at preclinical stages and not yet tested in patients.; No description in the abstract of a systematic search or meta-analytic pooling, so selection and summary methods are not specified..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveLimited evidenceTier 4 · clinicaln = 84⚠ Retracted
Computational and mathematical methods in medicine · Jun 2022 · randomized controlled trial
This randomized study assigned 84 patients with platinum-resistant recurrent ovarian epithelial carcinoma to receive olaparib plus bevacizumab (n=42) or albumin-bound paclitaxel plus bevacizumab (n=42). The authors report higher overall response rate, disease control rate, greater reductions in CA125/CA199/HE4 and changes in measured miRNAs, better quality-of-life improvement, and higher 1-, 2-, and 3-year survival rates in the olaparib+bevacizumab group. The abstract contains inconsistent P-value statements for survival (reports higher survival rates but lists "all P > 0.05"), and detailed dosing, adverse-event counts, and blinding are not provided.
Reported effects: Overall response rate (ORR) 69.05%, p both P < 0.05, n=84 · Disease control rate (DCR) 88.1%, p both P < 0.05, n=84 · +3 more
Studied with: bevacizumab.
Key findings
- Overall response rate (ORR) in the observation group was 69.05% versus 40.48% in the control group (both P < 0.05 as reported).
- Disease control rate (DCR) in the observation group was 88.10% versus 66.67% in the control group (both P < 0.05 as reported).
- After treatment, reductions in serum CA125, CA199, HE4 and changes in miRNA124, miRNA-21, and miRNA-203 were greater in the observation group than the control group (all P < 0.05 as reported).
- Quality-of-life improvement (FACT-G) was greater in the observation group than the control group (P < 0.05 as reported).
- Reported 1-, 2-, and 3-year survival rates were higher in the observation group (97.62%, 88.10%, 80.95%) than the control group (71.43%, 57.14%, 47.62%); the abstract states "with statistical significances (all P > 0.05)".
Limitations: Single-hospital (single-center) patient cohort as stated ('treated in our hospital'), limiting generalizability.; Small sample size (84 patients total; 42 per arm).; Abstract does not report doses or administration details of olaparib, bevacizumab, or albumin-bound paclitaxel.; Adverse event incidence was compared but numerical adverse-event data are not provided in the abstract.; Inconsistent P-value reporting for survival outcomes in the abstract (survival described as "with statistical significances (all P > 0.05)", which contradicts conventional significance thresholds).; Publication is marked as a retracted publication in the PubMed metadata..
AI summary of the abstract, human-reviewed · Aug 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportMechanismInconclusiveLimited evidenceTier 3 · early humann = 1
Clinical nuclear medicine · Sep 2020 · case report
This is a single-patient case report of a 39-year-old woman whose F-FDG PET/CT showed high uptake in a tumor in the pouch of Douglas and in metastatic sites; biopsy confirmed mesonephric carcinoma with metastases. She received six cycles of carboplatin, paclitaxel, and bevacizumab without sufficient response, after which checkpoint immunotherapy with nivolumab and ipilimumab was started.
Studied with: carboplatin + paclitaxel + bevacizumab, nivolumab + ipilimumab.
Key findings
- F-FDG PET/CT demonstrated high uptake in a tumor in the pouch of Douglas, in three pelvic lymph nodes, and in the left tuber ischiadicum.
- Biopsies showed a mesonephric carcinoma with metastases.
- Six series of empiric chemotherapy with carboplatin, paclitaxel, and bevacizumab were not sufficient to treat the cancer.
- Checkpoint immunotherapy with nivolumab and ipilimumab was initialized after chemotherapy.
Limitations: Single-patient case report (n=1).; No quantitative outcome data or follow-up provided after initiation of immunotherapy.; No doses, schedules, or treatment durations reported.; No control or comparison group..
Documents FDG-PET/CT avidity of metastatic mesonephric carcinoma and reports prior chemotherapy failure with subsequent initiation of combination checkpoint immunotherapy.
AI summary of the abstract, human-reviewed · Aug 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewInconclusiveLimited evidenceTier 3 · early humann = 69
Critical reviews in oncology/hematology · Jun 2018 · literature review
This is a literature review (search up to April 2017) of published studies on bevacizumab in uterine leiomyosarcoma. The authors pooled data on 69 patients with metastatic or unresectable disease and found pooled response rates of 35% objective response (complete + partial), 28% stable disease, 26% progressive disease, and 11% unknown. The addition of bevacizumab did not appear to increase grade 3 or worse toxicity, and data from the single randomized trial showed no difference in objective response rate compared with standard chemotherapy. The authors conclude current evidence does not support routine use and call for further randomized studies.
Reported effects: objective response (complete + partial) 35%, n=69 · stable disease 28%, n=69 · +2 more
Studied with: chemotherapy.
Key findings
- Literature search up to April 2017 identified data on 69 patients with metastatic, unresectable uterine leiomyosarcoma; no data on early-stage disease were found.
- Pooled response rates were 35% objective response (complete + partial), 28% stable disease, 26% progressive disease, and 11% unknown response.
- Addition of bevacizumab to standard treatment did not increase grade 3 or worse toxicity (assessed by CTCAE) according to pooled evidence.
- Data from the single randomized controlled trial indicated objective response rate did not differ from standard chemotherapy, limiting support for adding bevacizumab.
Limitations: Review article with small pooled sample (69 patients) drawn from multiple heterogeneous studies.; No data on early-stage uterine leiomyosarcoma reported.; Only one randomized controlled trial identified; limited randomized evidence.; Pooled response rates reported without confidence intervals or detailed methodology in the abstract.; Potential heterogeneity in patient populations, prior treatments, and chemotherapy partners across included studies is not detailed..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewMixed resultsLimited evidenceTier 4 · clinical
Therapeutics and clinical risk management · Dec 2015 · review
This review discusses bevacizumab for glioblastoma and summarizes prior findings. It says bevacizumab can promote tumor regression and reduce cerebral edema, and that adding it to standard chemoradiotherapy with temozolomide prolonged progression-free survival and improved performance status in newly diagnosed glioblastoma. However, it did not extend overall survival, and the review emphasizes balancing benefits and risks.
Studied with: temozolomide, chemoradiotherapy.
Key findings
- Bevacizumab was described as promoting tumor regression and improving cerebral edema.
- The review states that adding bevacizumab to standard chemoradiotherapy with temozolomide prolonged progression-free survival and improved performance status.
- The review states that overall survival was not extended.
- The review notes adverse events, especially hypertension and proteinuria, and that many other adverse events overlap with glioblastoma complications.
Limitations: This is a narrative review, not a primary study.; No new patient data or original analyses are presented in the abstract.; Quantitative effect sizes are not reported in the abstract.; The abstract does not specify the underlying studies' sample sizes or follow-up durations..
Review of bevacizumab use in glioblastoma, focusing on efficacy, safety, and clinical challenges.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 484
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jun 2012 · randomized, double-blind, placebo-controlled phase III trial
Bevacizumabplatinum-sensitive recurrent epithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase III trial tested bevacizumab added to gemcitabine and carboplatin in people with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer. The bevacizumab group had longer progression-free survival and a higher response rate than the placebo group. More high blood pressure and protein in the urine were seen with bevacizumab, but the study reported no new safety concerns overall.
Reported effects: PFS hazard ratio 0.484 [0.388–0.605], p < .0001, n=484 · median PFS 12.4 mo, n=484 · +3 more
Studied with: gemcitabine, carboplatin.
Key findings
- Bevacizumab plus gemcitabine/carboplatin improved progression-free survival versus gemcitabine/carboplatin plus placebo.
- Objective response rate and duration of response were also improved with bevacizumab.
- Grade 3 or higher hypertension and proteinuria were more frequent with bevacizumab.
Limitations: Progression-free survival was the primary endpoint; overall survival results are not reported in the abstract.; Safety follow-up details are limited in the abstract.; Adverse event reporting is summarized rather than fully detailed in the abstract..
This study evaluates bevacizumab as an added anticancer agent in recurrent gynecologic cancers.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMixed resultsModerate evidenceTier 4 · clinical
Journal of experimental & clinical cancer research : CR · Feb 2012 · review
BevacizumabCisplatinepithelial ovarian cancerprimary peritoneal carcinomaclear cell adenocarcinoma (ovarian)serous adenocarcinoma (ovarian) This review summarizes current therapeutic approaches for epithelial ovarian cancer, noting standard treatment is cytoreductive surgery plus taxane-and-platinum chemotherapy. It highlights that many apparent primary ovarian carcinomas may arise from the fimbria, that clear cell histology is relatively chemoresistant to carboplatin/paclitaxel and may respond to irinotecan plus cisplatin, and that targeted agents such as bevacizumab and PARP inhibitors are promising with some studies showing improved progression-free survival for bevacizumab.
Studied with: paclitaxel + platinum, irinotecan + cisplatin, bevacizumab (with chemotherapy).
Key findings
- Epithelial ovarian cancer is the most lethal gynecologic malignancy.
- Many tumors thought to be primary ovarian or peritoneal carcinomas may originate from the fimbria of the fallopian tube.
- Standard treatment is cytoreductive surgery plus combination chemotherapy using taxane and platinum.
- Clear cell ovarian carcinoma shows relative resistance to carboplatin and paclitaxel and therefore has poorer prognosis compared with serous adenocarcinoma in advanced stages.
- Irinotecan plus cisplatin therapy may be effective for clear cell adenocarcinoma.
- Bevacizumab (anti-VEGF) and PARP inhibitors are promising molecular targeted drugs in ovarian cancer.
- A few recent studies demonstrated positive results of bevacizumab on progression-free survival, but investigations of molecular targeted drugs in ovarian cancer are still underway.
Limitations: This publication is a review and does not present new primary data.; The abstract cites only 'a few recent studies' for bevacizumab, indicating limited summarized evidence in this text.; No quantitative results, sample sizes, or detailed trial designs are provided in the abstract.; Statements about efficacy for specific subtypes (e.g., clear cell) are not supported by detailed outcome data in the abstract..
Overview of therapeutic strategies and emerging targeted therapies for epithelial ovarian cancer.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Evidence at a glance: Bevacizumab by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Clear cell adenocarcinoma (ovarian)○Insufficient evidence◆Mixed results
No primary experimental studies yet.
Most authoritative study: Therapeutic strategies in epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
Malignant gliomas○Insufficient evidence◆Mixed results
No primary experimental studies yet.
Most authoritative study: Bevacizumab for glioblastoma
No human studies yet · No numeric effect sizes reported · Based on a single study.
Primary peritoneal carcinoma○Insufficient evidence◆Mixed results
No primary experimental studies yet.
Most authoritative study: Therapeutic strategies in epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
Serous adenocarcinoma (ovarian)○Insufficient evidence◆Mixed results
No primary experimental studies yet.
Most authoritative study: Therapeutic strategies in epithelial ovarian cancer
No human studies yet · No numeric effect sizes reported · Based on a single study.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.